All Type of News
Dr. Choi Ju-hyon named to head Sanofi Aventis Korea’s R&D operationsSanofi Aventis Korea said Wednesday it has appointed as its research development director, Choi Ju-yeon, a world-renowned expert in developing new drugs.
Choi will take char...
|
Drug vending machine outside pharmacy is not permissible: health ministrySales by drug vending machines at non-pharmacy places are deemed illegal as they violate the current Pharmaceutical affairs Law, the Ministry of Health and Welfare said on Wedne...
|
Hanmi to release generic Nexium in U.S. market shortly
Hanmi Pharmaceutical Co. on Tuesday announced that based on a confidential settlement agreement, a consent judgment has been entered by the United States District Court for the District of New Jersey with respect to t...
4 drug firms showing higher dependence of other licensing products
Korea’s four drug firms, such as Ilsung Pharm, Kwandong Pharm, Dongkook Pharm and Daewha Pharm, saw their dependence on other firms’ licensing products to gross sales jump in the first quarter of this year, data showe...
Innovative drug firms to face certification revocation
Last year, the government selected 43 companies as innovative pharmaceutical firms. Those in the category receive various benefits, including priority to participate in state-run research and development projects, tax...
On-line drug shopping malls exposed to fiercer competition
Pharmsnet, Korea’s on-line drug shopping mall leader, will not be as stable as before with Hanmi Pharm and Daewoong Pharm have entered the electronic commerce market to grab a bigger piece of the pie.
Amid the fier...
Celltrion completes Phase III clinical trials for CT-6P
Celltrion on Tuesday said that it has completed Phase III trials for its biosimilar candidate CT-P6 to demonstrate he comparable bioequivalence, efficacy and safety of CT-P6 to the reference drug.
CT-P6 is intended...
Korean drugmakers’ R&D spending falls slightly in 1Q
Korea’s 53 listed pharmaceutical companies saw their combined research and development (R&D) spending drop by 7.4 percent to 185.3 billion won, down 0.2 percent points from 7.6 percent a year ago, an online pharmaceut...
Takeda Korea receives MFDS approval for Nesina for type 2 diabetes
Takeda Korea Monday announced that the Ministry of Food and Drug Safety (MFDS) has approved Nesina (alogliptin) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
People with type 2 di...
Health Insurance covers Daxas from this month
The Ministry of Health and Welfare said Monday that national health Insurance has covered Takeda Pharm’s Daxas (roflumilast), an oral treatment of chronic obstructive pulmonary disease (COPD; a group of diseases that ...
